.Pharmacolibrary.Drugs.ATC.N.N01AX14 .Pharmacolibrary.Drugs.ATC.N.N01AX14| name: | Esketamine |
| ATC code: | N01AX14 | route: | intravenous |
| n-compartments | 2 |
Esketamine is the S-enantiomer of ketamine, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist. It is used as an anesthetic agent and, more recently, as an antidepressant for treatment-resistant depression. Esketamine nasal spray is approved for use in adults with treatment-resistant depression in combination with another oral antidepressant.
Pharmacokinetic model parameters obtained from healthy adult subjects after single-dose intravenous administration.
Perez-Ruixo, C, et al., & Perez-Ruixo, JJ (2021). Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression. Clinical pharmacokinetics 60(4) 501–516. DOI:10.1007/s40262-020-00953-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33128208
Jonkman, K, et al., & Dahan, A (2017). Pharmacokinetics and Bioavailability of Inhaled Esketamine in Healthy Volunteers. Anesthesiology 127(4) 675–683. DOI:10.1097/ALN.0000000000001798 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28759464
Kamp, J, et al., & Olofsen, E (2020). Pharmacokinetics of ketamine and its major metabolites norketamine, hydroxynorketamine, and dehydronorketamine: a model-based analysis. British journal of anaesthesia 125(5) 750–761. DOI:10.1016/j.bja.2020.06.067 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32838982